Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Senti Biosciences Announces New Employment Inducement Grants
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
Senti Bio to Present at BioJapan
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Senti Bio Participates in Nasdaq Amplify Spotlight Series
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Senti Biosciences Announces New Employment Inducement Grants
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Into Senti Biosciences Inc
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI